Rigel Pharmaceuticals heads into its May 14 earnings report as one of the more heavily shorted small-cap biotechs in the market — and yesterday's 12% price jump has done nothing to ease the tension.
Short sellers are meaningfully committed here. Short interest runs at 21.6% of the free float — roughly one in five shares outstanding is borrowed and sold. That is a material position, and it has barely moved over the past week: the ORTEX short score, which distils the overall bearish signal across lending, borrow, and positioning metrics, has held near 71 for more than two weeks. What is notable is that the borrow market remains remarkably relaxed despite the size of the short. Cost to borrow has barely stirred, running at just 0.53% annualised — essentially free to maintain a position. Days to cover stretch to 12 days by the official FINRA reading, so any rapid covering would be difficult and disorderly if the stock moves sharply. Options traders are edging slightly more defensive ahead of the print: the put/call ratio has climbed to 0.36, nearly two standard deviations above its 20-day average of 0.30. Still, the PCR is far below its 52-week high of 0.60, suggesting the options market is cautious but far from alarmed.
The bulls and bears are fighting over a genuinely cheap stock, at least on headline multiples. Rigel trades on a P/E of around 6.5x and an EV/EBITDA near 3.9x — both below sector norms for a profitable specialty pharma name. Bulls point to consistent quarter-over-quarter revenue growth from Fostamatinib, encouraging pipeline data in heavily pre-treated haematology patients, and the optionality embedded in the AstraZeneca royalty and milestone arrangement. The most recent analyst action confirms the constructive tone is still there: Citigroup's Yigal Nochomovitz trimmed his target to $69 from $71 on May 7 while holding a Buy rating — a modest adjustment that leaves the consensus mean target at $50.80 against a current price of $29.37, implying more than 70% implied upside from the sell-side. Bears counter with the patent cliff: Fostamatinib loses protection in 2032, and with no blockbuster replacement fully derisked in the pipeline, the risk is that the current earnings quality does not translate into durable franchise value. The stock fell 9.7% on the day after its last earnings print, on May 5, recovering most of that loss over the subsequent five days — a pattern of violent initial reactions followed by relative stability.
The ownership picture adds an interesting wrinkle. Soleus Capital, a healthcare-focused fund, disclosed a 668,000-share build as recently as May 6, lifting its stake to 5.2% of the company. State Street also added over 536,000 shares in the most recent quarter. That institutional accumulation runs directly into the sizeable short base, creating a structural tug-of-war that a clean earnings beat could catalyse. Insider activity is less informative: the most recent transactions in February were routine award grants followed by small tax-related sells at around $34–$36, with no signal of conviction buying or unusual distribution.
Tomorrow's report is therefore less about whether Rigel is profitable and more about whether Fostamatinib revenue is tracking ahead of the trajectory that justifies a 70%-plus gap to consensus target price — and whether the pipeline can offer any concrete evidence that the bear case on 2032 is premature.
See the live data behind this article on ORTEX.
Open RIGL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
